NCT03418038 2026-04-16
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
28 trialsNCT05554393 2026-04-16
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06317662 2026-04-16
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06458244 2026-04-16
The Efficacy of Allo-HSCT in ND HR-CBF-AML
Ruijin Hospital
Recruiting
NCT05564390 2026-04-15
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05849662 2026-04-15
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Recruiting
NCT05886049 2026-04-15
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07032727 2026-04-15
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03896269 2026-04-14
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04216524 2026-04-14
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05554406 2026-04-14
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06001788 2026-04-14
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
NCT06124157 2026-04-14
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06561152 2026-04-14
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Stanford University
Phase 1/2 Recruiting
NCT06504459 2026-04-13
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
OHSU Knight Cancer Institute
Phase 2 Recruiting
NCT06788756 2026-04-13
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Moleculin Biotech, Inc.
Phase 2/3 Recruiting
NCT07007312 2026-04-09
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Phase 3 Recruiting
NCT04049539 2026-04-08
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT06230224 2026-04-08
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT07514832 2026-04-07
VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial
Beijing 302 Hospital
Phase 2 Recruiting
NCT07514936 2026-04-07
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia
Chinese PLA General Hospital
Phase 2 Recruiting
NCT07223814 2026-04-06
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT06660368 2026-04-01
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT03959085 2026-03-31
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group
Phase 3 Recruiting
NCT06578247 2026-03-31
QuANTUM-WILD
Daiichi Sankyo
Phase 3 Recruiting
NCT00801489 2026-03-30
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05260528 2026-03-27
ALFA2101
Centre Hospitalier Universitaire de Nice
Phase 2 Recruiting
NCT06313437 2026-03-25
Revumenib in Combination With 7+3 + Midostaurin in AML
Dana-Farber Cancer Institute
Phase 1 Recruiting